Glaxo SmithKline
This article was originally published in The Tan Sheet
Executive Summary
Merger of Glaxo Wellcome and SmithKline Beecham likely will not require divestiture of their smoking cessation products, companies announce Dec. 12. Firms have reached an agreement with FTC in which SB will sell worldwide rights for Rx antivirals Vectavir/Denavir (penciclovir) and Famvir (famciclovir) to Novartis. The consent decree has been submitted to FTC and awaits review and approval; Glaxo and SmithKline expect completion of merger Dec. 27
You may also be interested in...
Citrucel Claim That Metamucil Causes Excess Gas Expelled After 20 Years
GlaxoSmithKline will discontinue claim P&G's Metamucil product causes excess gas and it Citrucel doesn't after P&G presented evidence that met NAD's standard for reopening a review. The industry self-regulation organization found GSK could no longer support its claim.
Glaxo Zantac 75 Divestiture To W-L Required By FTC
Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.
Glaxo Zantac 75 Divestiture To W-L Required By FTC
Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.